Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2019-03-01 Annual Report
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2018
2019-03-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2019, by AtriCure, Inc. It reports the issuance of a press release regarding financial results for the fourth quarter and full year ended December 31, 2018, and announces a conference call to discuss these results. The document explicitly states that the press release is furnished as an exhibit and is incorporated by reference, and that the information is being furnished and not filed. The document length is 3701 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. There are no actual financial statements or detailed financial data included in the text, only a reference to the press release and conference call. Therefore, this document is an announcement of financial results and related events, not the financial report itself. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain substantive financial data or the full report itself.
2019-02-28 English
FORM 4 SUBMISSION
Director's Dealing
2019-02-19 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-14 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-13 English
SEC SCHEDULE 13G
Major Shareholding Notification
2019-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.